Regeneron Pharmaceuticals (REGN)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$818.77+0.68%
Close 2026-10-29 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put REGN beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Maintain GAAP gross margin near 77%-80% in FY26: Gross margin: 86.56%.
View ThesisRevenue is growing steadily — about 9% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 13%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskREGN’s case rests on growing Dupixent, EYLEA HD, Libtayo, and its clinical pipeline. Revenue growth slowed from 19% to 17%, despite the latest quarterly earnings beat. REGN trades at 18× P/E versus the 21× peer median; expectations look modest versus our view. Our model puts the next-quarter miss probability near 24%. The thesis is on watch because the FY26 gross-margin pillar is under pressure against its 77%-80% range. Peer multiples imply a price roughly in line with where it trades (about fair). This read is provisional.
Trailing returns as of 2026-10-29. REGN is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 29 analysts currently covering REGN (as of Oct 2026).
Based on 16 Wall Street analysts offering 12-month price targets for REGN in the last 4 months.
Continue this research
Compare REGN with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| REGN Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put REGN next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Maintain and grow key product sales including Dupixent, EYLEA HD, Libtayo
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $818.77
The last 12 months of price, then the range of analyst 12-month targets from today’s $818.77.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Q3 beat and CFO outlook support product growth, though the headline gives no specific guidance details.
Advances: Maintain and grow key product sales including Dupixent, EYLEA HD, Libtayo
Revenue beat led by Dupixent supports key-product growth, though one quarter is not a structural change.
Advances: Advance clinical pipeline with ~50 candidates and new approvals
Initial durable-response data advance Regeneron's oncology pipeline, though remain early-stage.
Expanded immunology-antibody collaboration supports pipeline growth and long-acting product development.
Collaboration expansion with Sanofi extends partnered immunology development and commercial potential.
Advances: Advance clinical pipeline with ~50 candidates and new approvals
Reported 73% ovarian-cancer response rate is an encouraging pipeline signal, still early.
Advances: Advance clinical pipeline with ~50 candidates and new approvals
Expansion of alliance supports clinical pipeline advancement.
Advances: Advance clinical pipeline with ~50 candidates and new approvals
Expansion of alliance supports clinical pipeline growth.